Ubs Group Ag Atai Life Sciences N.V. Call Options Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
Call Options
1 transactions
Others Institutions Holding ATAI
# of Institutions
102Shares Held
23.7MCall Options Held
351KPut Options Held
170K-
Morgan Stanley New York, NY3.29MShares$13.8 Million0.0% of portfolio
-
Pale Fire Capital Se Prague, 2N2.59MShares$10.9 Million0.42% of portfolio
-
Davidson Kempner Capital Management LP New York, NY1.41MShares$5.92 Million0.07% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$5.48 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.14MShares$4.76 Million0.0% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $695M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...